Security Snapshot

Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) Institutional Ownership

CUSIP: 15117B202

13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

225

Shares (Excl. Options)

72,942,304

Price

$31.72

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-482,859
Value change
-$8,940,255
Number of holders
225
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
80,000,000
SEC-reported price per share
$32.51
Insider filing price
$32.51
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 is tracked under CUSIP 15117B202.
  • 225 institutions reported positions in Q1 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 183 to 225 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $1,992,599,502 to $2,312,963,417.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 225 institutions filings for Q1 2026.

Open SEC evidence

Security key

15117B202

Latest holder period

Q1 2026

13F holders

225

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
CLDX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 12% +10% $219,442,153 +$18,600,852 8,079,608 +9.3% Wellington Management Group LLP 31 Dec 2025
BlackRock, Inc. 7.3% -12% $100,867,802 -$13,842,621 4,819,293 -12% BlackRock, Inc. 31 Mar 2025
FMR LLC 5.6% -24% $117,195,241 -$34,655,461 3,749,048 -23% FMR LLC 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $109,332,337 3,446,795 Vanguard Capital Management 31 Mar 2026
Commodore Capital LP 4.6% -8% $78,343,026 -$8,321,474 3,028,335 -9.6% Commodore Capital LP 30 Sep 2025
STATE STREET CORP 4.2% -18% $87,658,292 -$18,554,217 2,804,168 -17% STATE STREET CORPORATION 31 Mar 2026
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% -36% $61,640,475 -$30,382,633 2,382,701 -33% T. Rowe Price Associates, Inc. 30 Sep 2025
Point72 Asset Management, L.P. 2.6% -59% $43,255,582 -$66,568,658 1,758,357 -61% Point72 Asset Management, L.P. 31 Dec 2025
EVENTIDE ASSET MANAGEMENT, LLC 2% $30,459,938 1,356,186 Eventide Asset Management, LLC 30 Jun 2025
Bellevue Group AG 1.5% -78% $37,512,000 -$75,576,333 1,200,000 -67% Bellevue Group AG 31 Mar 2026

As of 31 Mar 2026, 225 institutional investors reported holding 72,942,304 shares of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX). This represents 91% of the company’s total 80,000,000 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
70%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
WELLINGTON MANAGEMENT GROUP LLP 11% 8,560,476 +6% 0.05% $271,538,300
Kynam Capital Management, LP 7.3% 5,840,567 -1.7% 12% $185,262,785
BlackRock, Inc. 6.7% 5,369,885 -1.5% 0% $170,332,752
FMR LLC 4.7% 3,749,048 -24% 0.01% $118,919,804
Point72 Asset Management, L.P. 4% 3,229,939 +84% 0.18% $102,453,665
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 2,960,895 0% 0% $93,919,589
STATE STREET CORP 3.5% 2,804,168 -17% 0% $88,948,209
Commodore Capital LP 3.4% 2,696,616 +5.1% 4.9% $85,536,660
PRICE T ROWE ASSOCIATES INC /MD/ 2.6% 2,086,332 +2.3% 0.01% $66,179,000
Eversept Partners, LP 2.2% 1,788,016 +25% 3.7% $56,715,868
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,688,074 +3.7% 0% $53,556,480
BRAIDWELL LP 1.7% 1,356,082 -27% 1.4% $43,014,921
Deep Track Capital, LP 1.6% 1,283,979 -32% 0.84% $40,727,814
MILLENNIUM MANAGEMENT LLC 1.6% 1,253,532 +3.4% 0.03% $39,762,035
Vestal Point Capital, LP 1.5% 1,224,165 +5.1% 1.1% $38,830,514
Bellevue Group AG 1.5% 1,200,000 -67% 0.91% $38,064,000
NOVO HOLDINGS A/S 1.5% 1,200,000 0% 3.1% $38,064,000
DIMENSIONAL FUND ADVISORS LP 1.3% 1,059,534 +63% 0.01% $33,595,626
EVENTIDE ASSET MANAGEMENT, LLC 1.3% 1,037,000 -37% 0.54% $32,893,640
Fisher Asset Management, LLC 1.3% 1,013,648 +8.2% 0.01% $32,152,913
GOLDMAN SACHS GROUP INC 1.2% 988,416 -7.5% 0% $31,352,555
Pictet Asset Management Holding SA 1.2% 923,696 -4.6% 0.03% $29,299,637
Elmind Capital, LP 1.1% 865,000 0% 7.8% $27,437,800
AMERICAN CENTURY COMPANIES INC 1.1% 856,310 +0.13% 0.01% $27,162,211
BANK OF AMERICA CORP /DE/ 0.89% 708,647 +71% 0% $22,478,282

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
30
Latest
Q1 2026
Rows shown
1-25 of 30
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 72,942,304 $2,312,963,417 -$8,940,255 $31.72 225
2025 Q4 73,373,402 $1,992,599,502 +$45,987,039 $27.16 183
2025 Q3 70,729,708 $1,829,814,017 -$41,022,042 $25.87 180
2025 Q2 72,686,329 $1,479,214,886 -$18,971,957 $20.35 178
2025 Q1 73,628,376 $1,336,550,222 -$25,518,368 $18.15 170
2024 Q4 73,686,767 $1,861,792,917 -$10,935,353 $25.27 172
2024 Q3 71,809,989 $2,440,639,326 +$62,002,971 $33.99 174
2024 Q2 69,594,154 $2,575,716,559 +$1,332,092 $37.01 181
2024 Q1 69,311,318 $2,908,781,828 +$362,625,073 $41.97 196
2023 Q4 60,989,057 $2,418,831,729 +$410,573,840 $39.66 162
2023 Q3 50,572,705 $1,391,763,899 +$5,531,719 $27.52 140
2023 Q2 50,188,683 $1,702,972,802 +$19,493,416 $33.93 148
2023 Q1 49,503,692 $1,779,547,358 +$24,122,749 $35.98 158
2022 Q4 48,677,430 $2,169,609,749 -$9,316,822 $44.57 163
2022 Q3 49,338,461 $1,386,923,833 +$32,333,656 $28.11 146
2022 Q2 48,218,738 $1,300,004,065 -$45,672,202 $26.96 146
2022 Q1 49,602,527 $1,689,417,077 +$106,143,717 $34.06 157
2021 Q4 46,338,765 $1,790,195,856 +$97,400,922 $38.64 170
2021 Q3 43,227,306 $2,333,703,184 +$430,296,249 $53.99 156
2021 Q2 35,559,554 $1,189,106,240 +$60,325,552 $33.44 127
2021 Q1 34,503,199 $709,497,850 -$40,255,166 $20.60 109
2020 Q4 36,816,222 $645,045,236 +$72,177,637 $17.52 120
2020 Q3 32,156,087 $476,873,776 +$67,764,471 $14.83 82
2020 Q2 27,786,246 $361,216,517 +$310,785,532 $13.00 63
2020 Q1 3,949,694 $6,557,892 +$7,227 $1.66 32
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .